Paget’s disease of the breast is a rare intraepithelial malignancy involving the nipple–areola complex, often associated with an underlying in-situ or invasive carcinoma in the breast parenchyma. Most of the cases disease is usually limited to nipple–areola or surrounding periareolar skin. We are reporting a case of extensive Paget’s disease, involving entire breast skin and even part of abdominal wall skin without any underlining breast pathology, which is a rare presentation.
Background: There is paucity of data on the spectrum of breast diseases in India due to lack of reporting system. This study was conducted to understand the pattern of breast diseases in northwest India. It is by far the largest study to provide epidemiological data on breast disease spectrum in India.
Methods: Total of 8604 breast pathological reports were obtained from four major diagnostic centers in North West India. These included benign and malignant breast lesions.
Results: There were 5985 (69.56%) lesions in the benign group and 2619 (30.43%) lesions in malignant group. Women formed 92.73% (7978) of the study group. Among benign lesions, most common were discrete benign lumps 59.19% (3543) followed by fibrocystic changes 16.02% (959). The most common age group was ≤20 years for discrete benign lumps and gynecomastia whereas 31-40 years for fibrocystic changes. Among malignant lesions, the most common was infiltrating duct carcinoma (not otherwise specified) with 32.72% (857) followed by infiltrating duct carcinoma (moderately differentiated) 26.84% (703) with the most common age group of 41-50 years. Among breast lesions in men, male breast carcinoma formed 2.25% (59) of malignant breast lesions. Gynecomastia formed 0.65% (560) of all breast lesions.
Conclusions: Most common breast lesions were discrete breast lumps. Benign lesions are more common in early 20’s while malignant lesions are more common in the 5th decade. The study revealed a higher proportion of male breast carcinoma.
Cancers survivors with second tumour mass. The difficult thing in these situations is definitive diagnosis. One sentence which shapes the future of a patient-a steep see saw of definitive and palliative treatment. What saves the clinician in this scenario is the immunohistochemistry (IHC). It single handedly brightens the path and leads to conclusion. This case report demonstrated the same in breast cancer survivor.
Background: Gynecologic cancers form a huge burden of morbidity and mortality around the world. This study was undertaken to study the
pattern, histopathological types and relative frequencies of gynaecological malignancy cases reported at four major hospitals and pathology
centers in Jaipur region. Method: Retrospective review of records of gynecologic cancers obtained from four major pathology departments in
Jaipur region in which histopathological data of all female diagnosed with the genital tract malignancies for a ve year period were included in the
study. Results: Most common genital tract malignancy was cervical cancer (51.8%) followed by ovarian cancer (24.6%), uterine cancer (17.6%)
and vaginal cancer (3.96%). Mean ages for ovarian, uterine, endometrium, fallopian tube, vulva and cervical cancers were 42.79±15.84,
50.93±13.14, 61.21±7.61, 63.50±19.09, 56.05±17.89 and 51.29±11.95 years respectively. Conclusion & Recommendations: Cervix carcinoma
is the most common female genital tract malignancy followed by ovarian carcinoma and uterine cancer. Squamous type of cervical cancer was the
commonest type. Hospital facilities for screening and regular gynecological examinations and well-dened follow-up surveillance system can
change disease morbidity and mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.